Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma

J Small Anim Pract. 1996 May;37(5):241-6. doi: 10.1111/j.1748-5827.1996.tb01782.x.


An eight-year-old dog with a local relapse of an osteosarcoma was treated with partial maxillectomy and systemic radionuclide therapy that involved two injections, 43 and 45 megabecquerels per kg bodyweight of the bone-seeking agent samarium-153-ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP), 15 weeks apart. A transient drop in white blood cell count and platelet count was observed following each 153Sm-EDTMP treatment. Follow-up 21 months after surgery revealed no evidence of local recurrence or metastases. The dog was in excellent condition, suffering only minor sequelae from the surgical procedure. Compared with historical controls treated with surgery alone, the combination of surgery and systemic radionuclide therapy seems a promising strategy for the treatment of canine osteosarcoma.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Dog Diseases / diagnostic imaging
  • Dog Diseases / radiotherapy*
  • Dog Diseases / surgery*
  • Dogs
  • Female
  • Follow-Up Studies
  • Maxilla / surgery*
  • Maxillary Neoplasms / radiotherapy
  • Maxillary Neoplasms / surgery
  • Maxillary Neoplasms / veterinary*
  • Neoplasm Recurrence, Local / radiotherapy
  • Neoplasm Recurrence, Local / surgery
  • Neoplasm Recurrence, Local / veterinary*
  • Organometallic Compounds*
  • Organophosphorus Compounds*
  • Osteosarcoma / radiotherapy
  • Osteosarcoma / surgery
  • Osteosarcoma / veterinary*
  • Radioisotopes
  • Radionuclide Imaging
  • Radiotherapy, Adjuvant
  • Samarium


  • Organometallic Compounds
  • Organophosphorus Compounds
  • Radioisotopes
  • Samarium
  • samarium Sm-153 lexidronam